Whether the GRAF expression level could improve the stratification or prognostication
of patients with myeloid diseases should be further addressed in future studies. Acknowledgements This study was supported by Jiangsu Province’s Key Medical Talent Program (RC2007035) and Social Development Foundation of Zhenjiang (SH2006032). References 1. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2:249–256.PubMedCrossRef 2. Zhao J, Guan JL: Signal transduction by focal adhesion kinase in cancer. Dibutyryl-cAMP clinical trial Cancer Metastasis Rev 2009, 28:35–49.PubMedCrossRef 3. Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 2004, 64:3191–3197.PubMedCrossRef 4. Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal
N, Guyotat D: Prognostic value of CXCR4 and FAK expression in acute LY2874455 chemical structure myelogenous leukemia. Leuk Res 2009, 33:764–768.PubMedCrossRef 5. Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, Silberstein LE: FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am J Hematol 2009, 84:273–278.PubMedCrossRef 6. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O’Hare T, Heinrich MC, Deininger MW, Druker BJ: RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008, 111:2238–2245.PubMedCrossRef 7. Hildebrand JD, Taylor JM, Parsons JT: An SH3 domain-containing NVP-BGJ398 GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol 1996, 6:3169–3178. Epothilone B (EPO906, Patupilone) 8. Sahai
E, Olson MF, Marshall CJ: Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001, 20:755–766.PubMedCrossRef 9. Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D, Lampert F: The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000, 97:9168–9173.PubMedCrossRef 10. Bojesen SE, Ammerpohl O, Weinhäusl A, Haas OA, Mettal H, Bohle RM, Borkhardt A, Fuchs U: Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome. Br J Cancer 2006, 94:323–332.PubMedCrossRef 11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group.